TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stanford Accelerated Recovery Trial (START)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* Age 18 to 75~* Undergoing a scheduled surgery~* English speaking~* Ability and willingness to complete questionnaires or use Palm Pilot~EXCLUSION CRITERIA~* Known kidney disease~* Currently receiving gabapentin or (pregabalin) lyrica already~* Cognitive impairment~* Previous history of excessive sedation or adverse reaction to gabapentin (not it was tried but ineffective for nerve pain)~* Coexisting chronic pain \> 4/10 disorder in area other than surgical target~* Plan to move out of state~* Condition that would in judgment of team member make patient likely to be lost to follow-up~* Elevated suicidality~* Known pregnancy~* Current symptoms of ataxia, dizziness, or sedation~* Narrow angle glaucoma~* Severe respiratory insufficiency (ie, severe emphysema or chronic obstructive pulmonary disease)~* History of gastric bypass surgery and obstructive sleep apnea requiring continuous positive airway pressure (CPAP)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
- Gabapentin (Type: EXPERIMENTAL): 1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Ejaculatory Dyssynergia by Electronic Microsensors of Sphincters

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients evaluated by ejaculatory test during their usual care~* Men with spinal cord injury between 18 and 65 years old~* Patients who have given their informed consent~* Patients with social insurance affiliation~Exclusion Criteria:~* Minors~* Patients with justice protection~* Patients over 65 years old

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ejaculatory test (Type: EXPERIMENTAL): Measures of sphincter pressures during ejaculation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* odontogenic infection requiring tooth extraction asociated with amoxicillin monotherapy~* good condition~* 18-60 years old~* written informed consent provided~Exclusion Criteria:~* antibiotic prophylactic treatment~* special infectious risk (immunodeficiency, diabetes..)~* pregnant or breastfeeding women~* amoxicillin contraindication~* antibiotic treatment during the lasts 45 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 7-day amoxicillin treatment (1g per os twice daily)
- 2 (Type: ACTIVE_COMPARATOR): 3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ruxolitinib in Pancreatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas.~* Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~* Received 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy).~* ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.~* Radiographically measurable or evaluable disease~* An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:~  * Criteria:~    1. mGPS of 1: C-reactive protein (CRP) \> 10 mg/L and albumin ≥ 35 g/L~   2. mGPS of 2: CRP \> 10 mg/L and albumin \< 35 g/L~Exclusion Criteria:~* Received more than 1 prior regimen for advanced or metastatic disease.~* Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment~* Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).~* Current or previous other malignancy within 2 years of study entry without sponsor approval~* Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), ruxolitinib, or any of their excipients.~* Prior treatment with a JAK inhibitor for any indication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib plus capecitabine (Type: EXPERIMENTAL): None
- Placebo plus capecitabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Prior allogeneic hematopoietic stem cell transplant (+/- DLI)~* As per current recommendations, no interval from allo HSCT will be required to differentiate acute from chronic Graft versus Host Disease (GvHD)~* Patients must have had negative routine restaging PET-CT scans~* Patients may not have had any more than two weeks' specific treatment for chronic GvHD. (It is recognized that some patients develop chronic GvHD while on immunosuppressive prophylaxis; such patients will remain eligible, even if dose adjustment of these prophylactic agents occurs. The two week interval pertains to the use of additional agents in this case.)~* Diagnosis of chronic GvHD must be confirmed. In the usual case, tissue biopsy will be required; however, some chronic GvHD patients do not require tissue biopsy for confirmation. The PI and co-investigator must agree on eligibility.~* Per patient approval by PI and one additional co-investigator~* Informed consent~Exclusion Criteria:~* Patients with a malignancy not in remission will be excluded.~* Negative routine pregnancy testing. Patients either pregnant or unwilling to use satisfactory contraception (if appropriate) will not be eligible. All female patients must use a highly effective birth control method or a combination of 2 additionally effective birth control methods while in this study. Examples of highly effective birth control are: a condom or a diaphragm with spermicidal jelly, oral, injectable, or implanted birth control, or abstinence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET-CT (Type: EXPERIMENTAL): Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Diarrhea Using High and Low Osmolality Enteral Tube Feeding in Critically Ill Surgical Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>18 years~* admitted to SICU or CVICU requiring TF for enteral nutrition~* anticipated ICU stay and TF requirement \>72 hours~Exclusion Criteria:~* Contraindication to receiving one of the study TF formulations~* Inability to tolerate at least 75% of estimated requirement by day 3 of enteral TF administration~* Clostridium difficile infection or other cause of infectious diarrhea prior to study enrollment~* Presence of an ileostomy or colostomy~* History of inflammatory bowel disease, bowel resection, short gut syndrome, or chronic diarrhea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Promote without fiber (Type: ACTIVE_COMPARATOR): Lower osmolality enteral tube feed formulation
- Osmolite 1.5 (Type: ACTIVE_COMPARATOR): Higher osmolality enteral tube feed formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ≥18 years at the time of signing the informed consent~* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures~* Able to adhere to the study visit schedule and other protocol requirements~* Mild COVID-19 with outpatient management as decided by the treating physician~* Early warning score for 2019-nCoV infected patients ≤ 5~* Females of childbearing potential (FCBP1) must agree~* to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe~* to abstain from breastfeeding during study participation and 28 days after study drug discontinuation~* All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment~* All subjects must agree not to share medication~Exclusion Criteria:~* Requirement for oxygen administration~* Shortness of breath in resting position~* Creatinin \> 2.0 mg/dl~* Women during pregnancy and lactation~* Participation in other clinical trials or observation period of competing trials~* Active or clinically significant cardiac disease including congestive heart failure (New York Heart Association Class III or higher)~* History or current evidence of clinically significant cardiac arrhythmia except atrial fibrillation or paroxysmal supraventricular tachycardia~* Use of concomitant medications that prolong the QT/QTc interval~* Physician decision that involvement in the study is not in the patient´s best interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 600mg daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Equivalent number of placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients \> 18 years of age~* Histological confirmed colorectal adenocarcinoma~* Histological or clinically confirmed metastatic colorectal adenocarcinoma lesions (liver lesions only are considered as metastatic disease) and not resecable.~* A single liver lesion may not exceed 3 cm~* Liver lesions must not have a depth greater than 2 cm from hepatic surface (Glisson Capsule) (measured clinically if possible otherwise on the basis of CT/ultrasound examination)~* A life expectancy of at least 6 months.~* Patients with a ECOG performance status \< 2~* Signed Informed Consent~* Patient must be mentally capable of understanding the information given.~* Patient must give informed consent.~Exclusion Criteria:~* Age less than 18 years.~* Patient pregnant or lactating (no contraceptive method is contraindicated, a pregnancy test will be administered to all women of childbearing age)~* Life-threatening infection and/or heart failure and/or liver failure and/or other severe systemic pathologies that preclude laparotomy~* Strumental analysis confirmed ascites.~* Impaired kidney function.~* Significant reduction in respiratory function.~* Allergic reaction to bleomycin.~* Coagulation disturbances~* Patients with exclusion criteria for diagnostic MRI 3Tesla (with pace-makers and all those metal devices that are not compatible with 3T).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- electrochemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Inhaled Nitric Oxide for Respiratory Failure in Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants born at \>34 weeks gestational age~* Require assisted ventilation for hypoxic respiratory failure~* Have a diagnosis of primary persistent pulmonary hypertension (PPHN), respiratory distress syndrome, perinatal aspiration syndrome, pneumonia/sepsis, or suspected pulmonary hypoplasia~* Have an oxygenation index \>15 and \<25 based on 2 arterial blood gases taken at least 15 minutes apart or an Fi02 \>80%~* In-dwelling arterial line~* Parental consent~Exclusion Criteria:~* Known structural congenital heart disease, except patent ductus arteriosus and atrial level shunts~* Congenital diaphragmatic hernia~* Use of high frequency jet ventilation at the time of randomization~* Prior exposure to inhaled nitric oxide therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Early iNO Management (Type: EXPERIMENTAL): Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
- Standard iNO management (Type: ACTIVE_COMPARATOR): Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis must have been before the patient's 16th birthday~* Disease duration of at least 6 months before study entry~* Must have 5 or more joints with active arthritis~* Must be taking a stable dose of methotrexate 10-30 mg/meter squared (patients with body surface area \[BSA\] 1.67 square meter or more must be taking a minimum of 15 mg/week of methotrexate)~* May take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of NSAIDS (non-steroidal anti-inflammatory drugs) 2 weeks prior to entry~* Must have qualifying laboratory values at the first visit.~Exclusion Criteria:~* Have known allergies, hypersensitivity, or intolerance to golimumab or similar therapeutics~* Are pregnant or breast-feeding, or planning a pregnancy or fathering a child within 6 months after the last study agent administration~* Have initiated DMARDS and/or immunosuppressive therapy within 4 weeks prior to study initiation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- CNTO 148 (Golimumab) (Type: EXPERIMENTAL): All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
- Placebo (Type: PLACEBO_COMPARATOR): All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine in Treating Patients With Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed myelofibrosis with myeloid metaplasia (MMM), including any of the following subtypes:~  * Agnogenic myeloid metaplasia~ * Post-polycythemic myeloid metaplasia~ * Post-thrombocythemic myeloid metaplasia~* Evaluable and symptomatic disease, defined as 1 of the following:~  * Anemia (hemoglobin \< 10 g/dL or erythrocyte transfusion-dependent, requiring 1 transfusion ≤ 8 weeks)~ * Treatment required\* for symptomatic palpable splenomegaly (palpable hepatomegaly is acceptable if previously splenectomized) NOTE: \*Subjective but painful enough to mandate intervention~* Absence of t(9;22) by fluorescent in situ hybridization (FISH) or standard cytogenetics (by peripheral blood or marrow)~  - Previous demonstration of a lack of this translocation (at any point) is sufficient~* No advanced malignant hepatic tumors~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* Creatinine ≤ 2.0 mg/dL~* Total bilirubin ≤ 2.0 mg/dL OR direct bilirubin ≤ 2.0 mg/dL if total bilirubin elevated (unless attributed to underlying disease)~* AST and ALT ≤ 2 times upper limit of normal (unless clinically attributed to hepatic extramedullary hematopoiesis)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No baseline peripheral or autonomic neuropathy ≥ grade 2~* No condition, including the presence of laboratory abnormalities, that would preclude study compliance~* No hypersensitivity to mannitol or azacitidine~* Not incarcerated in a municipality (i.e., county, state, or federal prison)~PRIOR CONCURRENT THERAPY:~* At least 14 days since prior chemotherapy, including interferon alfa, anagrelide, or other myelosuppressive agents~* At least 14 days since prior systemic corticosteroids~* At least 14 days since prior investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy